^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    botensilimab (AGEN1181)

    i
    Company:
    Agenus
    Drug class:
    CTLA4 antagonist
    Related drugs:
    Apply
    Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (ARCITECT) (NCT05928806)
    Phase 2
    Michael B. Atkins, MD
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    09/25/2023
    Primary completion :
    10/10/2025
    Completion :
    10/12/2026
    CD4
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • balstilimab (AGEN2034) • botensilimab (AGEN1181)
    Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) (NCT05845450)
    Phase 2
    Gruppo Oncologico del Nord-Ovest
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    05/11/2023
    Primary completion :
    05/01/2026
    Completion :
    05/01/2028
    HER-2 • KRAS • BRAF • TMB • MSI • POLE • POLD1
    |
    HER-2 positive • MSI-H/dMMR • KRAS G12C • HER-2 amplification • HER-2 mutation • POLE mutation • KRAS wild-type • RAS wild-type • KRAS G12 • POLD1 mutation • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type
    |
    Imfinzi (durvalumab) • Vectibix (panitumumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Lumakras (sotorasib) • balstilimab (AGEN2034) • botensilimab (AGEN1181)
    FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer (NCI-2022-09458) (NCT05627635)
    Phase 1/2
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    02/12/2025
    Initiation :
    05/03/2023
    Primary completion :
    10/07/2025
    Completion :
    10/07/2025
    POLE
    |
    POLE mutation
    |
    Avastin (bevacizumab) • oxaliplatin • leucovorin calcium • balstilimab (AGEN2034) • botensilimab (AGEN1181) • fluorouracil topical
    Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer (C-800-01) (NCT03860272)
    Phase 1
    Agenus Inc.
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    03/20/2019
    Primary completion :
    01/13/2025
    Completion :
    12/01/2027
    ALK
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181)
    Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients with KRAS-Mutant Metastatic Colorectal Cancer (NCT06336902)
    Phase 1
    University of Southern California
    Recruiting
    Last update posted :
    02/03/2025
    Initiation :
    01/15/2025
    Primary completion :
    01/15/2027
    Completion :
    01/15/2028
    KRAS
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181)
    A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer (C-800-25) (NCT05608044)
    Phase 2
    Agenus Inc.
    Active, not recruiting
    Last update posted :
    06/04/2024
    Initiation :
    11/30/2022
    Primary completion :
    02/01/2025
    Completion :
    07/01/2025
    EGFR • BRAF • MSI
    |
    MSI-H/dMMR
    |
    Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil) • balstilimab (AGEN2034) • botensilimab (AGEN1181)
    Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases (NCT06300463)
    Phase 2
    Weill Medical College of Cornell University
    Recruiting
    Last update posted :
    04/12/2024
    Initiation :
    03/26/2024
    Primary completion :
    09/01/2025
    Completion :
    03/01/2027
    CD8
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181) • dalutrafusp alfa (AGEN1423)
    Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas (CIME) (NCT06346197)
    Phase 3
    Centre Leon Berard
    Not yet recruiting
    Last update posted :
    04/03/2024
    Initiation :
    05/15/2024
    Primary completion :
    05/15/2028
    Completion :
    05/15/2028
    TMB • LAG3 • TIGIT
    |
    Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • balstilimab (AGEN2034) • botensilimab (AGEN1181)
    Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer (NCT04121676)
    Phase 1
    Agenus Inc.
    Active, not recruiting
    Last update posted :
    04/01/2024
    Initiation :
    09/26/2019
    Primary completion :
    06/01/2025
    Completion :
    06/01/2027
    PD-L1 • BRAF
    |
    BRAF V600
    |
    botensilimab (AGEN1181) • AGEN2373
    A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma (NCT05529316)
    Phase 2
    Agenus Inc.
    Suspended
    Last update posted :
    01/12/2024
    Initiation :
    12/12/2022
    Primary completion :
    05/01/2028
    Completion :
    05/01/2028
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181)
    The Seven Trial: Exploiting the Unfolded Protein Response (NCT06076837)
    Phase 1
    HonorHealth Research Institute
    Not yet recruiting
    Last update posted :
    10/11/2023
    Initiation :
    12/01/2023
    Primary completion :
    06/01/2025
    Completion :
    12/01/2025
    CEACAM5 • MUC16
    |
    cisplatin • gemcitabine • albumin-bound paclitaxel • balstilimab (AGEN2034) • botensilimab (AGEN1181) • celecoxib oral • chloroquine phosphate
    Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy (NCT05672316)
    Phase 1/2
    City of Hope Medical Center
    Recruiting
    Last update posted :
    07/27/2023
    Initiation :
    05/11/2023
    Primary completion :
    11/09/2024
    Completion :
    11/09/2024
    PD-L1 • BRAF
    |
    BRAF wild-type
    |
    Stivarga (regorafenib) • balstilimab (AGEN2034) • botensilimab (AGEN1181)